Randomised Controlled Trial: Improvements in side effects of metastatic sarcoma patients (ASCO 2025)

SARC-Digital is a Randomised Controlled Trial (RCT) focusing on our personalised patient support solution, specifically for patients with advanced or metastatic sarcoma.

The trial’s interim results were shared with the scientific community at the annual meeting of the American Society for Clinical Oncology (ASCO) through an abstract highlighting its findings.

You can find below the key takeaways:

What is SARC‑Digital?

SARC‑Digital is a trial evaluating a digital health intervention designed specifically for patients with advanced or metastatic sarcoma. It has been developed to complement (and not replace) standard care. The intervention supports:

Ongoing symptom tracking.
Collection of patient-reported outcomes (PROs).
Tailored, automated support for specific side effects (SEs) reported by patients.
Remote Patient Monitoring (RPM) services to clinicians, with prompt reporting of SEs, individual patient records and summaries across patient groups.

The Trial: Measuring the impact on side effects

Patients with advanced sarcoma face substantial challenges regarding their quality of life. As per the trial’s design, the CareAcross platform randomises half of the participants to receive personalised, automated support for each of their reported SEs; the rest receive generic information.

Patients report their SEs by selecting among a pre-defined list of 10, which are commonly seen in advanced sarcoma patients and are amenable to self-care support.

Interim Analysis: substantial benefits from the CareAcross solution

At the time of submission to ASCO (early 2025), 50 patients had provided PROs with their SEs. Highlights from the analysis include:

The most frequent SEs are fatigue, constipation, nausea (reported by 78%, 52% & 50% of patients, respectively); the least frequent is lymphoedema (10%).
48 patients have submitted PROs at least twice, enabling improvement evaluation: Patients in the intervention arm experience higher rates of improvement of their SEs vs the control arm (71.52% vs 59.82%).
Among the 10 SEs, patients in the intervention arm exhibit higher improvement in 8, equal in 1, and lower in 1 SE.

These results point to the positive impact of digital, tailored support in enhancing symptom management for sarcoma patients.

You can read the study’s abstract here.

Looking ahead

The trial’s recruitment continues, and more data will become available regarding the impact on the patient experience as well as clinician workflows.

We look forward to sharing more details, updates and evidence from this innovative solution.

Acknowledgements